Deerfield Healthcare Technology Acquisitions Corp. Stock: price and management transactions · United States · SEC (Form 4)

About Deerfield Healthcare Technology Acquisitions Corp.

Deerfield Healthcare Technology Acquisitions Corp. (ticker: CMAX) is a United States-listed company that trades on the NASDAQ. The company began life in 2020 as a SPAC, or special purpose acquisition company, formed to complete a merger, stock exchange, asset acquisition, or similar business combination. That initial purpose was fulfilled through a business combination with CareMax, which effectively turned the vehicle into a health-care platform focused on value-based care and chronic disease management for seniors. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1813914/000095017023011018/cmax-20221231.htm?utm_source=openai)) From a business-model perspective, CMAX sits in the healthcare sector at the intersection of primary care delivery, care coordination, and technology-enabled physician support. The company’s filings and transaction materials describe a platform built around senior care, population health management, and data-driven decision tools for clinicians. In other words, the core thesis is not simply fee-for-service medical practice, but a more integrated model aimed at improving outcomes while managing cost and utilization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1813914/000110465921078429/tm2118826d4_ex99-1.htm?utm_source=openai)) Competitively, the company operates in a crowded U.S. market where value-based care providers must balance clinical quality, payer relationships, operating efficiency, and technology deployment. Its strategic appeal lies in combining medical services with analytics and workflow tools, potentially giving it a more integrated operating model than standalone physician groups. At the same time, competition is intense from managed-care platforms, healthcare consolidators, and digital health players pursuing similar economics. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1813914/000110465921078429/tm2118826d4_ex99-1.htm?utm_source=openai)) Geographically, the business is centered in the United States and is exposed to the U.S. reimbursement environment, including Medicare-linked economics. For international investors, it is important to note that CMAX is a U.S. public-market story tied to the NASDAQ rather than a European exchange listing. The company’s history also reflects the capital-markets complexity typical of SPAC-origin businesses, including PIPE financing and transaction-driven recapitalization. ([businesswire.com](https://www.businesswire.com/news/home/20210604005662/en/Deerfield-Healthcare-Technology-Acquisitions-Corp.-Announces-Stockholder-Approval-of-Business-Combination-With-CareMax?utm_source=openai)) Recent public information available in the sources reviewed is dominated by the CareMax transaction history and SEC filings that highlight the company’s post-combination capital structure and accounting evolution. Because no newer, fully verified operating update was available in the sources consulted, it is prudent not to overstate the current scale or performance. For investors, CMAX should therefore be viewed as a healthcare transformation story in the United States, with exposure to senior care, chronic disease management, and the execution risks of a post-SPAC listed company. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1813914/000095017024032506/cmax-20231231.htm?utm_source=openai))